Judith Quinlan Joins Cytel as Vice President, Adaptive Trials

Wednesday, May 14, 2008 General News J E 4
CAMBRIDGE, Mass., May 14 Cytel Inc., a leading provider ofclinical trial design services and specialized statistical software, todayannounced the appointment of Judith Quinlan as Vice President, AdaptiveTrials.

Judith Quinlan brings over twenty years of statistical experience to theCytel team. Prior to joining Cytel Judith spent 10 years with GSK, mostrecently as Statistics Director for biopharmaceuticals, and previously asStatistics Director for Neurology and GI. Throughout the last seven yearsshe's focused on bridging the gap between new clinical research concepts andthe challenging practicalities of conducting complex trials.

"Judith Quinlan has been a persistent and persuasive proponent of adaptiveclinical trials both at GSK, and through her work with the PhRMA Working Groupon Adaptive Designs (ADWG). This is helping pave the way toward the wideacceptance of innovative, flexible clinical study approaches. Judith combinesclinical theory and practice with a strategic business perspective on ClinicalDevelopment Programs. We are very pleased, indeed, to have Judith on board,"said Cytel's CEO, Ranganath Nayak.

In her new role, Judith Quinlan will guide Cytel's adaptive trial designand implementation offerings, leveraging her previous successes in managingcross-functional clinical research teams to drive more productive planning andimplementation of early stage and confirmatory trials. In addition tooverseeing Cytel's flourishing adaptive study efforts, Judith will continueher advocacy and education work as an active member of the PhRMA Working Groupon Adaptive Designs.

A popular speaker on adaptive trial design and operations, Judith Quinlanhas co-authored articles on numerous clinical research-related topics. Judithhas published in such prestigious journals as Pharmacotherapy andComputational Statistics, and she co-authored with Wyeth's Mike Krams theinfluential PhRMA group's paper on "Implementing Adaptive Designs: Logisticaland Operational Issues."

About Cytel

Cytel Inc. is a leading provider of clinical trial design services andspecialized statistical software for the biopharmaceutical, medical device,academic, and government research markets. Cytel's East(R) system is used bybiostatisticians and clinicians at hundreds of companies, throughout academiaand by regulators to design, simulate and monitor group sequential andadaptive clinical trials. Cytel provides trial sponsors with innovative tools,training, and consultation to increase process efficiencies and reducedevelopment costs.

SOURCE Cytel Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
NicOx Reports First Quarter 2008 Financial Results
FDA Approves AstraZeneca's Seroquel(R) for Mainten...